{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-23-000043","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.098823+00:00","generated_at":"2026-06-18T23:14:13.268113+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CareDx Q4 revenue $82.4M (+4% YoY); net loss widens to $18.3M; guides for H1 2023 EBITDA profitability","bullets":["Full year 2022 revenue $321.8M (+9% YoY); testing volumes up 19% to ~182,000 tests.","Q4 net loss $18.3M ($0.34 loss per share) vs $16.2M loss in Q4 2021; non-GAAP net loss $3.7M.","Adjusted EBITDA loss $3.7M in Q4 vs $1.4M loss; full year adjusted EBITDA loss $17.5M vs gain of $17.8M in 2021.","Cash and marketable securities $293M, no debt; authorized $50M share buyback, repurchased $0.6M in Q4.","Management targets adjusted EBITDA profitability in first half of 2023; ISHLT guidelines expanded use of HeartCare solutions."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-23-000043","json":"https://secwatch.observer/filing/0001217234-23-000043.json","markdown":"https://secwatch.observer/filing/0001217234-23-000043.md","text":"https://secwatch.observer/filing/0001217234-23-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/0001217234-23-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/cdna-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:14:13.268113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"506b66935d2bb62a572e7d9db406ae8454b77e73","claim":"CareDx, Inc. reported full year ended December 31, 2022 results: revenue $321.8 million, net income $76.6 million, EPS $1.44.","evidence_excerpt":"Revenue for the full year ended December 31, 2022, was $321.8 million, an increase of 9% compared with $296.4 million in 2021. Testing services revenue for the full year ended December 31, 2022 was $263.7 million, compared with $259.3 million in 2021. Product revenue for the full year ended December 31, 2022 was $29.3 million, compared to $26.8 million in 2021. Patient and digital solutions revenue for the full year 2022 was $28.8 million, compared to $10.3 million in 2021. Net loss for the full year ended December 31, 2022 was $76.6 million, compared to a net loss of $30.7 million in 2021. Basic and diluted net loss per share for the full year ended December 31, 2022 was $1.44, compared to basic and diluted net loss per share of $0.59 in the full year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/0001217234-23-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"$321.8 million"},{"label":"Net income","value":"$76.6 million"},{"label":"EPS","value":"$1.44"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e72b24b8f78e578d18af01602a905bcdc47980ef","claim":"CareDx, Inc. reported three months ended December 31, 2022 results: revenue $82.4 million, net income $18.3 million, EPS $0.34.","evidence_excerpt":"Revenue for the three months ended December 31, 2022 was $82.4 million, an increase of 4% compared with $79.2 million in the fourth quarter of 2021. Testing services revenue for the quarter was $65.4 million, compared with $68.7 million in the same period in 2021. Total AlloSure ® and AlloMap ® patient results provided in the quarter were 47,700, including 2,300 AlloSure ® Lung patient results. Product revenue in the three months ended December 31, 2022 was $8.6 million, compared to $7.7 million in the same period in 2021. Patient and digital solutions revenue in the fourth quarter of 2022 was $8.4 million, compared to $2.9 million in the same period in 2021. For the fourth quarter of 2022, net loss was $18.3 million, compared to a net loss of $16.2 million in the same period in 2021. Basic and diluted net loss per share in the fourth quarter of 2022 was $0.34, compared to basic and diluted net loss per share of $0.31 in the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1217234/000121723423000043/0001217234-23-000043-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2022"},{"label":"Revenue","value":"$82.4 million"},{"label":"Net income","value":"$18.3 million"},{"label":"EPS","value":"$0.34"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}